Trial reportAmerican journal of respiratory and critical care medicine2006
Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial.
Trial report in American journal of respiratory and critical care medicine, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 100 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
100 citing papers in PubMed, 4 syntheses or guidelines pooled it, 400 citations in OpenAlex.
- Antineutrophil cytoplasmic antibody-associated pachymeningitis: a systematic review of clinical features, diagnosis and treatment outcomes.Immunologic research · 2026Pooled it
- Guideline
- Efficacy of Rituximab on Refractory Organ Involvements in Granulomatosis with Polyangiitis: A Systematic Review of Case Reports.Current rheumatology reviews · 2024Pooled it
- Incidence of Cancer in ANCA-Associated Vasculitis: A Meta-Analysis of Observational Studies.PloS one · 2015Pooled it
- Efficacy of remission-induction regimens for ANCA-associated vasculitis.The New England journal of medicine · 2013Trial
- Rituximab for the treatment of Churg-Strauss syndrome with renal involvement.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2011Trial
- Rituximab versus cyclophosphamide for ANCA-associated vasculitis.The New England journal of medicine · 2010Trial
- Induction of remission in active anti-neutrophil cytoplasmic antibody-associated vasculitis with mycophenolate mofetil in patients who cannot be treated with cyclophosphamide.Annals of the rheumatic diseases · 2007Trial
- Infliximab in patients with systemic vasculitis that is difficult to treat: poor outcome and significant adverse effects.Annals of the rheumatic diseases · 2007Trial
- Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system.Annals of the rheumatic diseases · 2007Trial
- Rituximab in Connective Tissue Disease-Associated Interstitial Lung Disease: From Immunopathogenesis to Therapeutic Implications.International journal of molecular sciences · 2025Review
- Review
- Impact of Rituximab on Remission Rates in Granulomatosis With Polyangiitis: A Systematic Review.Cureus · 2024Review
- The Efficacy and Safety of Rituximab in ANCA-Associated Vasculitis: A Systematic Review.Biology · 2022Review
- Comparison of Two Rituximab Induction Regimens for Antineutrophil Cytoplasm Antibody-Associated Vasculitis: Systematic Review and Meta-Analysis.ACR open rheumatology · 2021Article
- Experience with similar biologic rituximab in 77 patients of granulomatosis with polyangiitis-a real-life experience.Clinical rheumatology · 2021Article
- Treatment of Diffuse Alveolar Hemorrhage: Controlling Inflammation and Obtaining Rapid and Effective Hemostasis.International journal of molecular sciences · 2021Review
- Ectopic Relapse of Anti-neutrophil Cytoplasmic Antibody-associated Pituitary Vasculitis with No Elevation of Anti-neutrophil Cytoplasmic Antibodies after Renal Remission.Internal medicine (Tokyo, Japan) · 2020Article
- Pathogenesis and treatment of autoimmune rheumatic diseases.Current opinion in rheumatology · 2019Review
- Long-term follow-up of a combined rituximab and cyclophosphamide regimen in renal anti-neutrophil cytoplasm antibody-associated vasculitis.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2019Article
40 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
rationaleStandard therapy for Wegener's granulomatosis is fraught with substantial toxicity and not always effective. B lymphocytes have been implicated in the pathogenesis of Wegener's granulomatosis. Their depletion has been proposed as salvage therapy for refractory disease. Earlier encouraging reports are confounded by concomitant immunosuppressive medications and include only limited available biomarker data.
objectivesTo evaluate the efficacy and safety of rituximab for remission induction in refractory Wegener's granulomatosis.
methodsA prospective open-label pilot trial was conducted with 10 patients monitored for 1 yr. Included were patients with active severe antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, ANCA positivity, and resistance to (or intolerance of) cyclophosphamide. The remission induction regimen consisted of oral prednisone (1 mg/kg/d) and four weekly infusions of rituximab (375 mg/m(2)). Prednisone was tapered and discontinued over 5 mo. Failure to achieve remission, a clinical flare in the absence of B lymphocytes, and inability to complete the glucocorticoid taper were considered treatment failures. MAIN
resultsThree women and seven men (median age, 57 yr; range, 25-72 yr) were enrolled. All had ANCA reacting with proteinase-3. The median activity score at enrollment was 6 (range, 5-10). All patients tolerated rituximab well, achieved swift B-lymphocyte depletion and complete clinical remission (activity score, 0) by 3 mo, and were tapered off glucocorticoids by 6 mo. Five patients were retreated with rituximab alone for recurring/rising ANCA titers according to protocol. One patient experienced a clinical flare after B lymphocyte reconstitution.
conclusionIn this cohort, rituximab was a well-tolerated and effective remission induction agent for severe refractory Wegener's granulomatosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.